Zolpidem: Restoring Sleep and Slowing Alzheimer Disease Progression

CONFERENCE REPORTER

At the SLEEP 2026 annual meeting, Ksenia Kastanenka, PhD, an assistant professor at Mass General Brigham, shared insights on her latest research about slowing the progression of Alzheimer disease. Here is how a common sleeping pill could reduce signs of the disease and improve brain function.

In a March 2026 study published in the journal Alzheimer’s and Dementia, Kastanenka and her team found that restoring healthy sleep in a mouse model of Alzheimer disease using zolpidem (also known as Ambien) reduced hallmark signs of the disease and improved overall brain function. Deficits in non-rapid eye movement (NREM) sleep facilitate Alzheimer disease progression, and enhancing gamma-aminobutyric acid (GABA)-ergic signaling can restore sleep. Their unbiased computational analysis then identified zolpidem as a high-affinity GABA receptor modulator facilitating chloride transport that could slow Alzheimer disease.¹

The team evaluated the effects of zolpidem on sleep and Alzheimer disease progression in young amyloid precursor protein/presenilin 1 (APP/PS1) mice. They monitored sleep via electroencephalography/electromyography (EEG/EMG) telemetry, and wide-field imaging with voltage-sensitive dyes was used to track sleep-dependent brain rhythms. Multiphoton microscopy allowed assessments of amyloid plaque load and basal neuronal calcium levels. The investigative team used behavioral assays to measure memory and cognitive function. They found that zolpidem restored NREM sleep and rescued sleep-dependent brain rhythm. Furthermore, the administration of zolpidem reduced cortical amyloid plaque burden, mitigated neuronal calcium overload, and enhanced sleep-dependent contextual recall without any adverse effects on movement.¹

These findings suggest that treatment of sleep issues could improve Alzheimer disease outcomes. Better yet, zolpidem is already approved by the US Food and Drug Administration, and could lead the way to slowing neurodegenerative disease progression.

Dr Kastanenka is an assistant professor at Massachusetts General Hospital and Harvard Medical School.

References

1. Yu L, Yokomizo S, Doan TH, et al. Zolpidem restores sleep and decreases amyloid in a mouse model. Alzheimers Dement. 2026;22(3):e71175.